Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei September 3, 2024 12:15 CET Regulatory Read more
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) September 3, 2024 12:00 CET Regulatory Read more
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis July 26, 2024 08:00 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) June 17, 2024 17:30 CET Regulatory Read more
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy May 30, 2024 20:00 CET Regulatory Read more
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation May 28, 2024 08:30 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) May 15, 2024 12:00 CET Regulatory Read more
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib May 6, 2024 08:00 CET Regulatory Read more
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO® March 6, 2024 08:15 CET Regulatory Read more
Calliditas Therapeutics provides business update ahead of JP Morgan conference January 8, 2024 08:15 CET Regulatory Read more
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital December 27, 2023 17:45 CET Regulatory Read more
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function December 20, 2023 22:15 CET Regulatory Read more
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO® December 11, 2023 15:15 CET Regulatory Read more
Calliditas announces additions to the management team December 1, 2023 09:00 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee composition for the AGM 2024 October 23, 2023 15:00 CET Regulatory Read more
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy August 18, 2023 10:00 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 30, 2023 16:00 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 28, 2023 08:30 CET Regulatory Read more
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy March 12, 2023 18:30 CET Regulatory Read more
Number of shares and votes in Calliditas Therapeutics January 31, 2023 08:00 CET Regulatory Read more
Number of shares and votes in Calliditas Therapeutics December 30, 2022 08:00 CET Regulatory Read more
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan December 13, 2022 08:00 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee composition for the AGM 2023 October 21, 2022 10:00 CET Regulatory Read more
European Commission approves Kinpeygo® for adults with primary IgA nephropathy July 15, 2022 17:00 CET Regulatory Read more
Issuance and repurchase of C-shares to establish an at-the-market program June 20, 2022 21:15 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 19, 2022 16:30 CET Regulatory Read more
Calliditas receives positive CHMP opinion in IgA nephropathy May 19, 2022 14:30 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 14, 2022 08:30 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2022 November 2, 2021 10:00 CET Regulatory Read more
Updated regulatory timeline for review of MAA in Europe. September 16, 2021 14:30 CET Regulatory Read more
PDUFA goal date extension for Nefecon NDA in the U.S. September 14, 2021 21:10 CET Regulatory Read more
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million August 12, 2021 23:55 CET Regulatory Read more
Calliditas Therapeutics intends to carry out a directed share issue August 12, 2021 17:04 CET Regulatory Read more
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe July 21, 2021 08:45 CET Regulatory Read more
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency May 28, 2021 14:40 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 27, 2021 18:30 CET Regulatory Read more
FDA grants priority review for Nefecon, for patients with IgA nephropathy April 28, 2021 09:50 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 26, 2021 12:00 CET Regulatory Read more
EMA Grants Accelerated Assessment Procedure for Nefecon for the Treatment of IgA Nephropathy April 23, 2021 08:30 CET Regulatory Read more
Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy March 15, 2021 07:30 CET Regulatory Read more
Calliditas announces termination of the proposed global offering January 28, 2021 14:40 CET Regulatory Read more
Calliditas Therapeutics launches proposed global offering January 26, 2021 22:10 CET Regulatory Read more
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day January 20, 2021 08:00 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2021 November 27, 2020 16:00 CET Regulatory Read more
Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial November 8, 2020 12:45 CET Regulatory Read more
Calliditas closes acquisition of a controlling interest in Genkyotex SA November 3, 2020 15:15 CET Regulatory Read more
Number of shares and votes in Calliditas Therapeutics September 30, 2020 10:00 CET Regulatory Read more
Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA August 13, 2020 07:00 CET Regulatory Read more
Exercise of over-allotment option and end of the stabilization period July 2, 2020 08:45 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) June 25, 2020 18:30 CET Regulatory Read more
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market June 24, 2020 22:45 CET Regulatory Read more
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market June 12, 2020 23:00 CET Regulatory Read more
Calliditas Therapeutics prices its initial public offering on The Nasdaq Global Select Market in the United States June 5, 2020 08:40 CET Regulatory Read more
Calliditas Therapeutics launches US IPO roadshow and targets a capital raise of MUSD 75 June 1, 2020 13:00 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) May 26, 2020 12:00 CET Regulatory Read more
Calliditas publicly files registration statement with SEC for a proposed initial public offering in the United States May 14, 2020 15:00 CET Regulatory Read more
Calliditas moves its Annual General Meeting 2020 to June 25 March 30, 2020 14:00 CET Regulatory Read more
Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ) March 3, 2020 12:45 CET Regulatory Read more
Notice of extraordinary general meeting of Calliditas Therapeutics AB (publ) January 31, 2020 08:30 CET Regulatory Read more
Calliditas submits draft registration statement for the listing of ADSs in the U.S. January 9, 2020 17:35 CET Regulatory Read more
Completion of recruitment of Part A of the NeflgArd pivotal Phase 3 clinical trial by year end December 19, 2019 08:00 CET Regulatory Read more
China IND approval triggers $5 million milestone payment from Everest Medicines December 17, 2019 11:40 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2020 November 11, 2019 10:00 CET Regulatory Read more
Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon October 1, 2019 08:00 CET Regulatory Read more
Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study September 3, 2019 07:00 CET Regulatory Read more
Strategic in-licensing related to autoimmune hepatitis in the US market August 12, 2019 14:40 CET Regulatory Read more
Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million July 3, 2019 08:00 CET Regulatory Read more
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore June 10, 2019 08:00 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 8, 2019 18:30 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 4, 2019 09:01 CET Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis February 12, 2019 11:15 CET Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis February 5, 2019 10:15 CET Regulatory Read more
Bulletin from extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ) December 14, 2018 16:15 CET Regulatory Read more
Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ) November 14, 2018 08:00 CET Regulatory Read more
First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon November 13, 2018 16:20 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2019 October 4, 2018 10:00 CET Regulatory Read more
Exercise of over-allotment option and end of the stabilization period July 29, 2018 18:30 CET Regulatory Read more
Calliditas announces listing on Nasdaq Stockholm and related prospectus June 15, 2018 05:00 CET Regulatory Read more
